Nucleus Laboratories (India) Limted - Due diligence report

A 360° intelligence report on Nucleus Laboratories (India) Limted: trust score, financial health, credit view, compliance, directors, growth…

1999-12-07 Lucknow, Uttar Pradesh Active Unlisted Active Compliant
Share
NL Nucleus Laboratories (India) Limted
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Nucleus Laboratories (India) Limted — 360° Intelligence Report

Generated from MCA filings & public records
76/100
Trust Score
Low Risk

Nucleus Laboratories (India) Limted is assessed as Low Risk with a Trust Score of 76/100. Nucleus Laboratories (India) Limted is an active public limited indian non-government company incorporated in 1999, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and high financial risk profile.

Report generated on 17 Jul 2026 from the latest processed filings. Nucleus Laboratories (India) Limted snapshot & full profile →

Financial Health › Weak
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
76/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
100/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
40/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
45/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
50/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 45/100 Caution Indicated
  • Negative operating earnings - debt service depends on external support.
  • Working-capital cover adequate.

Charges position: 1 open (30.00 Lakh) · 0 satisfied (-).

Banking relationships (from registered charges)
LenderChargesAmount
Bank Of India1 48.0 cr
Compliance Score: 100/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
ASHISH KUMAR SINGH 01234567 Director 01/04/2018 6 yrs Approved
Debashish Saha 01234567 Director 01/04/2018 6 yrs Approved
GYAN PRAKASH SHRIVASTAVA 01234567 Director 01/04/2018 6 yrs Approved
CHANDANA SHRIVASTAVA 01234567 Director 01/04/2018 6 yrs Approved
Himani Shukla 01234567 Director 01/04/2018 6 yrs Approved
  • 5 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2017)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2020 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
3 allotment(s) · 1 transfer(s)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 75 · Distress 50
Growth signals & trust indicators
Revenue acceleration: +38% over 4 year(s).
Asset base grew 1.42 - capacity expansion.
Operating for 26+ years.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Losses deepening year-on-year.
Outside liabilities up 2.1x in a year.
1 open charge(s) registered - assets are encumbered.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence78/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 3 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment57/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 1 open charge(s) of 30.00 Lakh already registered.
  • Compliance record supports lending.
Investor view63/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 2 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2025
Last AGM held
Annual general meeting
01 Aug 2025
Director appointed
Himani Shukla (Director)
31 Mar 2025
Latest balance sheet
Filed with ROC
01 Jun 2023
Director appointed
Debashish Saha (Director)
Director ceased
AVADHESH PRATAP SINGH
Director ceased
SUPRIYA SINGH
07 Mar 2022
Director appointed
GYAN PRAKASH SHRIVASTAVA (Director)
Director appointed
CHANDANA SHRIVASTAVA (Director)
17 May 2021
Securities allotted
20000 Equity Shares Without Differential Rights - 20.00 Lakh raised
28 Mar 2019
Director ceased
PUSHPA SINGH
02 Jun 2018
Charge created
Bank Of India - 30.00 Lakh
30 Nov 2016
Director ceased
SANTOSH KUMAR SINGH
Director ceased
ABHISHEK KUMAR SINGH
31 Mar 2016
Share transfer (FY 2016)
4430 shares to KUMAR ABHISHEK
08 Feb 2010
Securities allotted
625 Equity Shares Without Differential Rights - 62,500.00 raised
10

Key Observations

Auto-generated from the data above
Revenue grew 24% over the last 4 financial year(s).
Net profit margin moved from 0.86 to 61%.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
5 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 3 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Spaa Pure Seed Genetics Private Limited U51101MP2015PTC034841 Indore, Madhya Pradesh, India
Cusp International Private Limited U52300DL2009PTC189724 New Delhi, Delhi, India
Jai Bajrang Agrofarm Private Limited U15400BR2012PTC019689 Kochas, Bihar, India
Gennext Crop Science Private Limited U51501DL2013PTC249517 Delhi, Delhi, India
Palazhi Super Market Private Limited U52100KL2014PTC037653 Kozhikode, Kerala, India
Ra Excellent Confections Private Limited. U15432MH2007PTC170721 Thane, Maharashtra, India
Nutan Design Mart Private Limited U31909RJ2012PTC039477 Udaipur, Rajasthan, India
Madhav Krg Re Cyclers Private Limited U37100PB2007PTC046507 Mandi Gobindgarh, Punjab, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Nucleus Laboratories (India) Limted before audits and certifications: compliance score 100/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Nucleus Laboratories (India) Limted: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 45/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 75/100, margin trends, ownership structure and peer set for Nucleus Laboratories (India) Limted - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 76/100, distress signals and MSME payment-delay disclosures - know whether Nucleus Laboratories (India) Limted pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Nucleus Laboratories (India) Limted - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Nucleus Laboratories (India) Limted an active company?

Nucleus Laboratories (India) Limted has MCA status “Active” with a compliance score of 100/100 (Low Risk).

Is Nucleus Laboratories (India) Limted financially healthy?

Nucleus Laboratories (India) Limted has a Financial Health Score of 40/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Nucleus Laboratories (India) Limted?

Its overall Trust Score is 76/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Nucleus Laboratories (India) Limted?

See the directors and ownership sections above for board and shareholding detail. 5 active director(s) are on record.

Does Nucleus Laboratories (India) Limted have loans or charges against its assets?

1 open charge(s) are registered against its assets.

Is Nucleus Laboratories (India) Limted up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 100/100 (Low Risk).

Is it risky to lend to Nucleus Laboratories (India) Limted?

Its Credit Risk Score is 45/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.